BENZOTHIOPHENE COMPOUNDS

Abstract: This invention is directed to a class of acrylic and propionic acid compounds and their use in the treatment of post-menopausal symptoms and restenosis. In other embodiments, the invention is directed to intermediates and to processes for the preparation of the acrylic and propionic acid compounds.

Description: BENZOTHIOPHENE COMPOUNDS This invention relates to the fields of pharmaceutical and organic chemistry and provides novel acrylic and propionic acid compounds which are useful for the treatment of various medical indications associated with post-menopausal syndrome. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compoundε. The invention also provides novel methods of treatment and compositions useful in carrying out the methods. "Post-menopausal syndrome" iε a term used to describe various pathological conditions which frequently affect women who have entered into or completed the physiological metamorphosis known as menopause. Although numerous pathologieε are contemplated by the use of this term, two major effects of post-menopausal syndrome are the source of great long-term medical concern: osteoporosis and cardiovascular effects such as hyperlipidemia. Osteoporosis describeε a group of diεeases which arise from diverεe etiologieε, but which are characterized by the net loss of bone mass per unit volume. The consequence of thiε loεε of bone maεε and resulting bone fracture iε the failure of the skeleton to provide adequate structural support for the body. One of the most common typeε of osteoporosiε iε that aεεociated with menopause. Most women lose from about 20% to about 60% of the bone mass in the trabecular compartment of the bone within 3 to 6 years after the ceεεation of menses. This rapid losε iε generally aεεociated with an increaεe of bone reεorption and formation. However, the reεorptive cycle iε more dominant and the reεult iε a net loεε of bone maεε. Osteoporoεiε iε a common and seriouε diseaεe among poεt-menopausal women. There are an estimated 25 million women in the United States, alone, who are afflicted with this disease. The results of osteoporosis are personally harmful and also account for a large economic loss due its chronicity and the need for extensive and long term εupport (hospitalization and nursing home care) from the disease sequelae. This is especially true in more elderly patients. Additionally, although osteoporosis is not generally thought of as a life threatening condition, a 20% to 30% mortality rate is related with hip fractureε in elderly women. A large percentage of thiε mortality rate can be directly aεεociated with poεt- menopausal osteoporosis. The most vulnerable tissue in the bone to the effects of post-menopausal osteoporoεiε is the trabecular bone. This tissue is often referred to as εpongy or cancellouε bone and iε particularly concentrated near the ends of the bone (near the joints) and in the vertebrae of the spine. The trabecular tissue is characterized by small osteoid structures which inter-connect with each other, as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This inter-connected network of trabeculae gives lateral support to the outer cortical structure and is critical to the bio¬ mechanical strength of the overall structure. In post- menopausal oεteoporoεiε, it iε, primarily, the net reεorption and loss of the trabeculae which leads to the failure and fracture of bone. In light of the loss of the trabeculae in post-menopausal women, it is not εurprising that the most common fractures are those associated with bones which are highly dependent on trabecular support, e.g., the vertebrae, the neck of the weight bearing bones such as the femur and the fore-arm. indeed, hip fracture, collies fractures, and vertebral crush fractures are hall-marks of post-menopausal osteoporosis. At this time, the only generally accepted method for treatment of post-menopausal osteoporosis is estrogen replacement therapy. Although therapy is generally successful, patient compliance with the therapy is low primarily because estrogen treatment frequently produces undesirable side effects. Throughout premenopausal time, most women have less incidence of cardiovascular disease than age-matched men. Following menopause, however, the rate of cardiovascular diεeaεe in women slowly increases to match the rate seen in men. This loεε of protection has been linked to the loss of estrogen and, in particular, to the loss of estrogen's ability to regulate the levels of serum lipids. The nature of eεtrogen'ε ability to regulate serum lipids is not well understood, but evidence to date indicates that eεtrogen can upregulate the low denεity lipid (LDL) receptors in the liver to remove excess cholesterol. Additionally, estrogen appears to have some effect on the biosynthesis of cholesterol, and other beneficial effects on cardiovascular health. It has been reported in the literature that post¬ menopausal women having estrogen replacement therapy have a return of serum lipid levels to concentrations to those of the pre-menopausal εtate. Thuε, estrogen would appear to be a reasonable treatment for this condition. However, the side-effects of estrogen replacement therapy are not acceptable to many women, thus limiting the use of this therapy. An ideal therapy for this condition would be an agent which would regulate the serum lipid level as does estrogen, but would be devoid of the side-effectε and riεkε asεociated with eεtrogen therapy. In reεponεe to the clear need for new pharmaceutical agentε which are capable of alleviating the εymptoms of post-menopausal syndrome, the present invention provides new acrylic and propionic acid compounds, pharmaceutical compositions thereof, and methods of using εuch compounds for the treatment of osteoporosiε and the cardiovascular effects of poεt-menopauεal εyndrome. The preεent invention alεo provides these same acrylic and propionic acid compounds for the treatment of restenoεis. Smooth aortal muscle cell proliferation plays an important role in diseases such as atherosclerosis and restenosis. Vascular restenosis after percutaneous transluminal coronary angioplaεty (PTCA) haε 'been shown to be a tissue response characterized by an early and late phase. The early phase occurring hours to days after PTCA is due to thrombosis with some vasospasms while the late phase appears to be dominated by excessive proliferation and migration of aortal smooth muscle cells. In this disease, the increased cell motility and colonization by such muscle cells and macrophages contribute significantly to the pathogenesis of the disease. The excessive proliferation and migration of vascular aortal smooth muscle cells may be the primary mechanism to the reocclusion of coronary arteries following PTCA, atherectomy, laser angioplasty and arterial bypass graft surgery. See "Intimal Proliferation of Smooth Muscle Cells as an Explanation for Recurrent Coronary Artery Stenosiε after Percutaneouε Tranεluminal Coronary Angioplaεty," Auεtin et al . , Journal of the American College of Cardiology. £: 369-375 (Aug. 1985) . Vascular restenosis remains a major long term complication following surgical intervention of blocked arteries by percutaneous transluminal coronary angioplasty (PTCA) , atherectomy, laser angioplasty and arterial bypass graft surgery. In about 35% of the patientε who undergo PTCA, reoccluεion occurε within three to six months after the procedure. The current strategies for treating vascular restenosis include mechanical intervention by devices such as stents or pharmacologic therapies including heparin, low molecular weight heparin, coumarin, aspirin, fish oil, calcium antagonist, εteroids, and prostacyclin. These strategieε have failed to curb the reocclusion rate and have been ineffective for the treatment and prevention of vascular restenosis. See "Prevention of Restenosis after Percutaneous Transluminal Coronary Angioplasty: The Search for a 'Magic Bullet'," Hermans et al . , American Heart Journal. 122: 171- 187 (July 1991) . In the pathogenesis of reεtenoεiε, exceεsive cell proliferation and migration occurs as a reεult of growth factors produced by cellular constituents in the blood and the damaged arterial vesεel wall which mediate the proliferation of εmooth muεcle cells in vascular restenoεiε. Agentε that inhibit the proliferation and/or migration of smooth aortal muscle cells are useful in the treatment and prevention of restenosis. The present invention provideε for the uεe of compounds as smooth aortal muscle cell proliferation inhibitors and, thus inhibitors of restenosis. The present invention relates to compounds of Formula I: wherein each of R and R 1 is independently hydrogen, hydroxy, C 1 -C 4 -alkoxy, benzyloxy, Ci-C δ -alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituentε each of which is independently halo, C 1 -C 4 - loweralkyl, or Cι-C 4 -loweralkoxy, Ci-Cs-alkoxycarbonyloxy, or C 4 -C 6 -alkylsulfonyloxy; R 3 is -CH=CH- (tranε) or -CH 2 -CH 2 -; R 4 is hydroxy, Cι-C 4 -alkoxy, or -N(R 5 ) 2 wherein each R 5 is taken separately and independently represents hydrogen or Cχ-C 6 -alkyl, or both R 5 are taken with the N atom and constitute pyrrolidino, piperidino, hexamethyleneimino, or morpholino; or a pharmaceutically acceptable salt thereof. Preferred compounds are those wherein R3 = -CH=CH- ( trans ) ; R 4 = -OH (including salts) or -OEt ; or R and R 1 = OH or OCH 3 . Compounds embodying multiple preferences, in any combination, are also preferred. Also provided by the present invention are intermediate compounds of Formula Ia, which are useful for preparing the pharmaceutically active compounds of the present invention, and which are shown below wherein each of R and R l is independently hydrogen, C 1 -C 4 - alkoxy, benzyloxy, C 2 -C6-alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituents each of which is independently halo, Cι-C 4 -loweralkyl, or Cι-C 4 -loweralkoxy, Cι- 5 -alkoxycarbonyloxy, or C 4 -C6-alkylsulfonyloxy. The present invention further relates to pharmaceutical compositions containing compounds of Formula I, optionally containing estrogen or progestin, and the use of such compounds, alone, or in combination with estrogen or progeεtin, for alleviating the εymptomε of post-menopausal syndrome, particularly osteoporosis and cardiovascular related pathological conditions. The compounds of the present invention also are expected to be useful in inhibiting aortal εmooth muscle cell proliferation, particularly restenosis, in humans. Most of the compounds of Formula I are made by conversion of the formylbenzoyl compounds of Formula Ia: This conversion is an example of a Horner-Emmons reaction, which iε discussed in detail by adsworth in Organic Reactions, 1977, 25, 73-253, which is incorporated herein by reference. The conversion of the p-formylbenzoyl compounds is achieved by reacting a compound of Formula Ia with the carbanion of a trialkyl phosphonoacetate. This carbanion is generated by pretreating the trialkyl phosphonoacetate with a strong baεe, such as n-butyllithium, sodium hydride, and DBU. The reaction is conducted in an inert εolvent; suitable such solvents include tetrahydrofuran, dioxane, benzene, 1,2- dimethoxyethane, and diethyl ether. The reaction is conducted at temperatures of from -78° to 0°. The amounts of the reactants are not critical; the reaction consumes equimolar amounts of the p-formylbenzoyl compound and the trialkyl phosphonoacetate carbanion. The product is isolated from the reaction mixture in conventional manner. In Formula Ia, Ra and R la represent any of the groups defined for R and R 1 exclusive of hydroxy. This reaction is conducted with any hydroxy group having first been protected. Hydroxy protection is well known; see, for example, Protective Groups in Organic Chemistry, Plenum Press (London and New York, 1973); Protecting Groups in Organic Synthesis, Wiley (New York, 1981); and The Peptides . Vol. I, Schrooder and Lubke, Academic Presε (London and New York, 1965) . Hydroxyl protection iε also discusεed in 4,418,068, which is incorporated herein by reference. The following R and R 1 groups are in the nature of hydroxy protecting groups : Cι-C 4 -alkoxy, benzyloxy, Cχ-C 6 -alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituents each of which is independently halo, Cχ-C 4 -loweralkyl, or C 1 -C 4 - loweralkoxy, Ci-Cs-alkoxycarbonyloxy, and C 4 -C 6 - alkylεulfonyloxy. These compounds are primarily useful as chemical intermediates, but some of them exhibit useful biological activity in addition. Other compounds of the present invention are prepared in standard manners well known to those skilled in the art. The free acids (R 4 = OH) are prepared by hydrolysis; the resulting acids can be reacted subsequently with alkanols to form other esters, or with amines to form the amides. Deprotection of the hydroxy protecting groups iε done by well known procedureε, which are diεcuεεed in the reference cited above. Hydrogenation of the R 3 = -CH=CH- compoundε yields the corresponding R 3 = -CH 2 -CH 2 - compounds. Therefore, in one embodiment the present invention is directed to a method of preparing a compound of Formula Ib. wherein each of R a and R la is independently hydrogen, C 1 -C 4 - alkoxy, benzyloxy, C 2 -C 6 -alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituents each of which is independently halo, Cι-C 4 -loweralkyl, or C_-C 4 -loweralkoxy, Cι_ 5 -alkoxycarbonyloxy, or C 4 -C 6 -alkylsulfonyloxy; R 3 is -CH=CH- (trans) ; and R iε Cι-C 4 -alkoxy, which comprises reacting a compound of Formula la with a trialkyl phosphonoacetate carbanion in an inert solvent at a temperature from -78° to 0°. Optionally, any one or more additional reactions are thereafter conducted: hydrolyzing the ester to an acid, removing hydroxy protecting groups, hydrogenating CH=CH to CH 2 -CH 2 , and converting the acid to an ester, amide, or salt. The present compounds can be used for the purposeε described herein in the free-acid form (R 4 = hydroxy) . However, it is feasible and sometimeε preferred to use pharmaceutically acceptable saltε, such as an ammonium salt; or an inorganic alkali metal salt, e.g., sodium or potassium, or an organic amine salt such as methylamine, diethylamine, triethylamine, pyridine, morpholine, n-butylamine, and octadecylamine. The preparation of such εalts is well known. Typically the compound of Formula I iε reacted with an equimolar or exceεs amount of base. The reactants are generally combined in a mutual inert solvent; the salt normally precipitates out of solution and can be isolated by filtration, or the solvent can be removed by conventional meanε. The p-formylbenzoyl compounds, Formula Ia, repreεent another embodiment of the preεent invention. They are prepared by the following reaction scheme: 3)H 3 O + 3) acetone, pTsOH - which is more fully illustrated by Preparationε 1-3, below. The benzo[b]thiophenes which are employed aε εtarting materialε are prepared as described in U.S. Patents 4,418,06! and 4,133,814, which are incorporated herein by reference. The latter of these also describes the preparation of the 1- carboxy-2-phenylbenzo[b] hiophenes, by another route than above. Preparation 1 6 - ethoxy-2 - ( 4 -methoxyphenyl ) - 3 -bromo- benzo [b] hiophene . SUBSTTTUTE 5HEET (RULE 26) To a solution of 6-methoxy-2- (4- methoxyphenyl)benzo[b] thiophene (27.0 g, 100 mmol) in 1.10 L of CHCI 3 at 60 °C was added bromine (15.98 g, 100 mmol) dropwise as a solution in 200 mL of CHCI 3 . After the addition was complete, the reaction was cooled to room temperature, and the solvent removed in vacuo to provide 34.2 g (100%) of 6-methoxy-2- (4-methoxyphenyl) -3- bromobenzo[b]thiophene as a white solid, mp 83-85 °C. 1 H NMR (DMSO- <j) δ 7.70-7.62 (m, 4H) , 7.17 (dd, J = 8.6, 2.0 Hz, IH) , 7.09 (d, J = 8.4 Hz, 2H) . FD mass spec: 349, 350. Ana-Z. Calcd. for Cι 6 Hι 3 θ 2 SBr: C, 55.03; H, 3.75. Found: C, 54.79; H, 3.76. Preparation 2 Preparation of 6-methoxy-2- (4-methoxyphenyl) 3-carboxybenzo [b] thiophene . 6-Methoxy-2- (4-methoxyphenyl) -3- bromobenzo[b]thiophene (15.0 g, 42.9 mmol) was dissolved in 300 mL of anhydrous THF under N 2 and cooled to -70°C. To thiε solution was added nBuLi (29.6 mL, 47.4 mmol, 1.6 M εolution in hexanes) dropwise via syringe. After stirring at -70 °C for 20 min, a steady stream of CO 2 (g) was introduced into the reaction mixture for 15 min. The mixture was allowed to gradually warm to 0°C and then quenched by pouring the mixture into cold 1 N HCl (500 mL) . The aqueous layer was extracted with EtOAc (3 x 300 mL) . The organic layer was dried (Na S0 4 ) and concentrated in vacuo to a solid. The crude product waε chromatographed (Siθ 2 , 25% EtOAc/hexaneε) to provide 9.35 g (69%) of 6-methoxy-2- (4-methoxyphenyl)-3- carboxybenzo[b]thiophene aε a white solid, mp 166-170 °C. NMR (DMSO-cJV) δ (doubling due to rotamers) 13.0-12.8 (bε) , 8.10 and 7.68 (d, J = 8.1 Hz, IH) , 7.63 and 7.47 (d, J = 8.6 Hz, 2H) , 7.59 and 7.54 (d, J = 2.0 Hz, IH) , 7.10 and 6.97 (dd, J = 8.1, 2.0 Hz, IH) , 7.02 (d, J = 8.6 Hz, 2H) , 3.83 and 3.79 (ε, 3H) , 3.82 and 3.80 (ε, 3H) . FD mass spec: 315. Anal. Calcd. for C 17 H 14 O 4 S: C, 64.95; H, 4.49. Found: C, 65.19; H, 4.32. Preparation 3 6-methoxy-3- (4-formylbenzoyl) -2- (4- methoxyphenyl)benzo [b]thiophene. To a solution of 6-methoxy-2- (4-methoxyphenyl)-3- carboxybenzo[b]thiophene (4.00 g, 12.74 mmol) in 100 mL of anhydrous CH 2 CI 2 was added thionyl chloride (3.0 mL, 38.22 mmol) along with 0.1 mL of DMF. The resulting mixture was heated to reflux for 5 h. Upon cooling, the solvent and excess thionyl chloride were removed in vacuo to give the acid chloride as a yellow oil. The acid chloride was then dissolved in 75 mL of THF under N 2 . In a separate flask, 4-bromobenzaldehyde diethyl acetal (3.65 g, 14.0 mmol) was diεsolved in 50 mL of anhydrous THF under N 2 and cooled to -78 °C. To this solution was added nBuLi (8.,76 mL, 14.0 mmol, 1.6 M solution in hexanes) dropwise via syringe. After stirring for 20 min at -78 °C, the solution was transferred via cannula to a -78 O 3 -VCr solution of the acid chloride. The resulting mixture was allowed to gradually warm to room temperature, and then quenched by pouring into cold 0.2 N NaOH (200 mL) . The aqueous was extracted with EtOAc (2 x 200 mL) . The organic layer was dried (Na 2 S0 4 ) and concentrated in vacuo to give crude 6-methoxy-3- [ (4-diethoxymethyl)benzoyl] -2- (4- methoxyphenyl)benzo[b] thiophene as a yellow oil. This material was immediately dissolved in 200 mL of reagent grade acetone, and pTsOH (150 mg) was added. After εtirring for 30 min at room temperature, TLC indicated that the diethyl acetal had been converted to aldehyde. The reaction was quenched by the addition of anhydrous K 2 CO 3 (500 mg) . After removal of the solids by filtration, the filtrate was concentrated in vacuo to a dark oil that was chromatographed (Si0 2 , hexanes/EtOAc) to provide 1.70 g (33%) of 6-methoxy-3- (4-formylbenzoyl-2- (4-methoxyphenyl)benzo [b]thiophene aε a yellow εolid. mp 147-150°C. ^-H NMR (DMSO-d^) δ 10.03 (ε, IH) , 7.85 (ε, 4H) , 7.70 (d, J = 2.2 Hz, IH) , 7.57 (d, J = 9.0 Hz, IH) , 7.28 (d, J = 9.0 Hz, 2H) , 7.06 (dd, J = 9.0, 2.2 Hz, IH) , 6.84 (d, J = 9.0 Hz, 2H) , 3.67 (s, 3H) , 3.86 (s, 3H) . FD mass spec: 402. Example 1 ( E ) -6-methoxy-3- [4- (2- (carboxyvinyl )benzoyl] - 2- ( 4-methoxyphenyl )]benzo tb] thiophene, ethyl ester. To a -78 °C solution of triethyl phosphonoacetate (0.70 mL, 3.43 mmol) in 20 mL of anhydrous THF under N 2 was added nBuLi (2.41 mL, 3.43 mmol, 1.6 M solution in hexanes) dropwise via syringe. After stirring for 20 min at -78 °C the solution was transferred via cannula to a -78 °C solution of 6-methoxy-3- (4-formylbenzoyl) -2- (4- methoxyphenyl)benzo[b]thiophene (1.15 g, 2.86 mmol) in 20 mL of anhydrous THF. The reaction mixture was allowed to gradually warm to room temperature whereupon the reaction was judged complete by TLC analysis. The reaction was quenched by distributing between H 2 O/CHCI 3 . The organic layer was dried (Na 2 Sθ 4 ) and concentrated in vacuo to an oil that was chromatographed (Siθ 2 , CH 2 CI 2 ) to provide 1.25 g (93%) of (E) - 6-methoxy-3-[4- (2- (carboxyvinyl)benzoyl]-2- (4- methoxyphenyl)benzo[b]thiophene, ethyl ester, as a yellow oil. ^ NMR (DMSO-d^) δ 7.74-7.66 (m, 5H) , 7..62 (d, J = 16.0 Hz, IH) , 7.45 (d, J = 9.0 Hz, IH) , 7.30 (d, J = 9.0 Hz, 2H) , 7.03 (dd, J = 9.0, 2.2 Hz, IH) , 6.87 (d, J = 9.0 Hz, 2H) , 6.70 (d, J = 16 Hz, IH) , 4.19 (q, J = 7.0 Hz, 2H) , 3.85 (s, 3H) , 3.69 (s, 3H) , 1.25 (t, J = 7.0 Hz, 3H) . FD masε εpec: 473. Anal. Calcd. for C 28 H 24 θ 5 S«l.5 H 2 0: C, 67.32; H, 5.45. Found: C, 67.09; H, 5.05. Example 2 ( E) -6-methoxy-3- [4- (2-carboxyvinyl)benzoyl] 2- (4-methoxyphenyl) ]benzo[b]thiophene. (E) -6-methoxy-3-[4- (2- (carboxyvinyl)benzoyl]-2- (4- methoxyphenyl)benzo[b]thiophene (1.15 g, 2.43 mmol) was dissolved with gentle warming on a steam bath in a mixture of 10 mL THF, 15 mL 2.0 N NaOH, and 5 mL of EtOH. After stirring for 1 h, the solution was acidified to pH 3 using 1.0 N HCl. The aqueous was extracted with EtOAc (3x) . The organic was dried (Na 2 Sθ ) and concentrated to give 900 mg (83%) of (E) -6-methoxy-3-[4- (2-carboxyvinyl)benzoyl] -2- (4- methoxyphenyl)benzo[b] thiophene, as a yellow solid. mp 204- 207 °C. λ H NMR (DMSO-d^) δ 12.60 (bs, IH) , 7.69 (bε, 5H) , 7.55 (d, J = 16.0 Hz, IH) , 7.45 (d, J = 9.0 Hz, IH) , 7.30 (d, J = 8.5 Hz, 2H) , 7.03 (dd, J = 9.0, 2.2 Hz, IH) , 6.87 (d, J = 8.5 Hz, 2H) , 6.59 (d, J = 16.0 Hz, IH) , 3.85 (s, 3H) , 3.70 (s, 3H) . FD mass spec: 444. Anal. Calcd. for C 26 H 20 O 5 S: C, 70.26; H, 4.54. Found: C, 70.02; H, 4.55. Example 3 ( E) -6-hydroxy-3- [4- (2-carboxyvinyl)benzoyl] - 2- (4-hydroxyphenyl)benzo [b] thiophene . To a -5 °C solution of 6-methoxy-3- [4- (2- carboxyvinyl)benzoyl] -2- (4-methoxyphenyl)benzotb]thiophene (900 mg, 2.0 mmol) in 40 mL of anhydrous CH 2 CI 2 under N 2 was added BBr 3 (0.76 mL, 8.0 mmol) slowly via syringe. After warming to 5 °C, the mixture was stirred for 1 h at 5°C, then quenched by pouring into ice water (100 mL) . The mixture was extracted with EtOAc (3 x 100 mL) . The organic was then dried (Na 2 S0 4 ) and concentrated in vacuo to a solid residue that was chromatographed (Siθ 2 , 1% MeOH/CHCl 3 ) to provide 730 mg (86%) of (E) -6-hydroxy-3- [4- (2- carboxyvinyl)benzoyl] -2- (4-hydroxyphenyl)benzo[b]thiophene as a yellow solid. mp 155-160 °C. ^-H NMR (DMSO-d<j) δ 12.55 (bs, IH) , 9.81 (ε, IH) , 9.73 (ε, IH) , 7.67 (s, 4H) , 7.54 (d, J = 16.0 Hz, IH) , 7.40 (d, J = 9.0 Hz, IH) , 7.30 (d, J = 2.5 Hz, IH) , 7.18 (d, J = 9.0 Hz, 2H) , 6.89 (dd, J = 9.0, 2.5 Hz, 1H) , 6.65 (d, J = 9.0 Hz, 2H) , 6.58 (d, J = 16.0 Hz, IH) . FD mass spec: 416. Anal . Calcd. for C 24 H 3.6 O 5 S: C, 69.22; H, 3.87. Found: C, 68.95; H, 3.73. i Example 4 6-hydroxy-3- [4- (2-carboxyethyl )benzoyl] -2- (4 hydroxyphenyl)benzo [b] thiophene. 6-hydroxy-3- [4- (2-carboxyvinyl)benzoyl] -2- (4- hydroxyphenyl)benzo[b] thiophene (310 mg, 0.74 mmol) was dissolved in 50 mL of a 1:1 mixture of EtOH and EtOAc. This solution was hydrogenated at 40 psi in the presence of 10% Pd/C (200 mg) . When the reaction was judged complete by TLC analysis, the mixture was filtered through Celite to remove the catalyst. The filtrated was concentrated in vacuo to a yellow oil that was triturated from hexanes/EtOAc. Filtration provided 225 mg (72%) of 6-hydroxy-3- [4- (2- carboxyethyl)benzoyl] -2- (4-hydroxyphenyl)benzo [b]thiophene as a yellow solid, mp 244-248 °C. 1 H NMR (DMSO-d^) δ 12.15 (bs, IH) , 9.74 (s, IH) , 9.68 (s, IH) , 7.56 (d, J = 8.1 Hz, 2H) , 7.30 (d, J = 2.0 Hz, IH) , 7.23-7.19 (m, 3H) , 7.12 (d, J = 8.5 Hz, 2H) , 6.82 (dd, J = 9.0, 2.0 Hz, IH) , 6.62 (d, J = 8.5 Hz, 2H) , 2.77 (t, J = 7.0 Hz, 2H) , 2.45 (t, J = 7.0 Hz, 2). FD maεs spec: 418. Anal. Calcd. for C 24 H 18 O 5 S.2O H 2 0: C, 68.89; H, 4.34. Found: C, 68.35; H, 4.72. Test Procedure General Preparation Procedure In the examples illuεtrating the methodε, a post¬ menopausal model was used in which effectε of different treatmentε upon circulating lipids were determined. Seventy-five day old female Sprague Dawley rats (weight range of 200 to 225g) were obtained from Charles River Laboratories (Portage, MI) . The animals were either bilaterally ovariectomized (OVX) or exposed to a Sham surgical procedure at Charles River Laboratories, and then shipped after one week. Upon arrival, they were housed in metal hanging cages in groups of 3 or 4 per cage and had ad libitum access to food (calcium content approximately 0.5%) and water for one week. Room temperature was maintained at 22.2° ± 1.7° C with a minimum relative humidity of 40%. The photoperiod in the room was 12 hours light and 12 hourε dark. Dosinσ Reσimen Tiεεue Collection. After a one week acclimation period (therefore, two weekε post-OVX) daily dosing with test compound was initiated. 17α-ethynyl estradiol or the test compound were given orally, unless otherwise stated, as a suεpenεion in 1% carboxymethylcelluloεe or dissolved or suspended in 20% cyclodextrin. Animals were dosed daily for 4 days. Following the dosing regimen, animals were weighed and anesthetized with a ketamine: Xylazine (2:1, V:V) mixture and a blood sample was collected by cardiac puncture. The animals were then sacrificed by asphyxiation with CO 2 , the uteruε was removed through a midline incision, and a wet uterine weight waε determined. Choleεterol Analvεiε. Blood εamples were allowed to clot at room temperature for 2 hours, and serum was obtained following centrifugation for 10 minutes at 3000 rpm. Serum cholesterol was determined using a Boehringer Mannheim Diagnostics high performance cholesterol assay. Briefly the cholesterol was oxidized to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide waε then reacted with phenol and 4-aminophenazone in the preεence of peroxidaεe to produce a p-quinone imine dye, which waε read εpectrophotometrically at 500 nm. Cholesterol concentration was then calculated against a standard curve. The entire assay was automated using a Biomek Automated Workεtation. Uterine Eosinophil Peroxidase (EPO) Assav. Uteri were kept at 4° C until time of enzymatic analysis. The uteri were then homogenized in 50 volumes of 50 mM Tris buffer (pH - 8.0) containing 0.005% Triton X-100. Upon addition of 0.01% hydrogen peroxide and 10 M O-phenylenediamine (final concentrations) in Tris buffer, increase in absorbance was monitored for one minute at 450 nm. The presence of eosonophils in the uterus is an indication of eεtrogenic activity of a compound. The maximal velocity of a 15 εecond interval was determined over the initial, linear portion of the reaction curve. Source of Compound: 17α-ethynyl estradiol was obtained from Sigma Chemical Co., St. Louis, MO. Influence of Formula I Compoundε on Serum Cholesterol and Determination of Agonist Activity Data presented in Tables 1 and 2 below εhow comparative results among ovariectomized rats, rats treated with 17α-ethynyl estradiol (EE 2 ; an orally available form of estrogen) , and rats treated with certain compounds of the present invention. Although EE 2 caused a decrease in serum cholesterol when orally administered at 0.1 mg/kg/day, it alεo exerted a stimulatory action on the uterus so that EE 2 uterine weight was substantially greater than the uterine weight of ovariectomized test animals. This uterine response to estrogen iε well recognized in the art. The compoundε of the preεent invention at a doεe of 10 mg./kg. reduced εerum cholesterol compared to the ovariectomized control animals. Uterine weight waε εomewhat increaεed but thiε increaεe waε εignificantly leεε than waε obεerved with EE 2 . As is expreεεed in the below data, eεtrogenicity also was assessed by evaluating the adverse responεe of eoεinophil infiltration into the uteruε. The compoundε of the preεent invention did not cause any significant increase in the number of eosinophils observed in the stromal layer of ovariectomized rats, while estradiol cause a substantial, expected increase in eosinophil infiltration. The data presented in Tables 1 and 2 below reflect the responεe of 5 to 6 rats per treatment. Tabi e 1 Dose Uterine Weight Uterine EPO Serum Compound mg/kg (% increase (V. max) Cholesterol (% vs. OVX) decrease vs. OVX) EE 2 0.1 201.3 130.5 68.6 Example 2 0.1 25.0 2.1 -16.6 CDX 1 23.3 2.1 -37.3 susp. 10 119.9 35.1 73.2 Example 3 0.1 23.9 0.9 -15.1 CDX 1 19.7 1.2 -26.6 soln. 10 97.3 8.4 57.7 Example 4 0.1 -45.9 0.0 -46.2 CDX 1 -37.0 0.0 -28.8 soln. 10 29.3 1.2 16.5 Table 2 Dose Uterine Weight Uterine EPO Serum Compound mg/kg (% increase (V. max) Cholesterol (% vs. OVX) decrease vs . OVX) EE2 0.1 197.3 216.3 93.8 Example 3 0.1 3.1 0.9 20.7 CDX 1 6.7 2.1 30.0 soln. 10 139.7 22.2 74.1 In addition to the demonstrated benefits of the compounds of the present invention, especially when compared to estradiol, the above data clearly demonstrate that compounds of Formula I are not estrogen mimetics. Furthermore, no deleterious toxicological effects (survival) were observed with any treatment. The present invention also provides a method of alleviating post-menopausal syndrome in women which comprises the aforementioned method using compounds of Formula I and further comprises administering to a woman an effective amount of estrogen or progestin. These treatments are particularly useful for treating osteoporosis and lowering serum cholesterol because the patient will receive the benefits of each pharmaceutical agent while the compounds of the present invention would inhibit undesirable side-effects of estrogen and progestin. As used herein, the term "estrogen" includes steroidal compounds having estrogenic activity such as, for example, 17β-estradiol, eεtrone, conjugated eεtrogen (Premarin®) , equine eεtrogen, 17β-ethynyl eεtradiol, and the like. As used herein, the term "progestin" includes compounds having progeεtational activity such as, for example, progesterone, norethylnodrel, nongestrel, megestrol acetate, norethindrone, and the like. Various forms of estrogen and progestin are commercially available. Estrogen-baεed agentε include, for example, ethynyl eεtrogen (0.01 - 0.03 mg/day), mestranol (0.05 - 0.15 mg/day), and conjugated estrogenic hormones such as Premarin® (Wyeth-Ayerst; 0.3 - 2.5 mg/day). Progestin- based agents include, for example, medroxyprogesterone such as Provera® (Upjohn; 2.5 -10 mg/day), norethylnodrel (1.0 - 10.0 mg/day), and nonethindrone (0.5 - 2.0 mg/day). A preferred estrogen-based compound is Premarin, and norethylnodrel and norethindrone are preferred progestin- baεed agents. The method of administration of each estrogen- and progestin-baεed agent iε consistent with that which is known in the art. For the majority of the methods of the present invention, compounds of Formula I are administered continuouεly, from 1 to 3 times daily. However, cyclical therapy may especially be preferred. In the- case of restenosis, therapy may be limited to short (1-6 months) intervals following medical procedures such as angioplasty. As used herein, the term "effective amount" means an amount of compound of the present invention which is capable of alleviating the symptoms of the various pathological conditionε herein deεcribed. The εpecific doεe of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the state of being of the patient, and the pathological condition being treated. A typical daily dose will contain a nontoxic dosage level of from about 5 mg to about 600 mg/day of a compound of the preεent invention. Preferred daily doεes generally will be from about 15 mg to about 80 mg/day. The compounds of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranaεal. These compoundε preferably are formulated prior to administration, the selection of which will be decided by the attending physician. Thus, another aspect of the present invention is a pharmaceutical composition comprising an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, optionally containing an effective amount of estrogen or progestin, and a pharmaceutically acceptable carrier, diluent, or excipient. The total active ingredientε in εuch formulationε compriεeε from 0.1% to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent, excipients and salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof. Pharmaceutical formulations of the present invention can be prepared by procedureε known in the art using well known and readily available ingredients. For example, the compounds of Formula I, with or without an estrogen or progestin compound, can be formulated with common excipients, diluentε, or carriers, and formed into tablets, capsules, suεpenεions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenderε such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl¬ pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding diεεolution εuch aε paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers εuch aε kaolin and bentonite; and lubricantε such as talc, calcium and magnesium εtearate, and εolid polyethyl glycolε. The compounds also can be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular physiological location, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes. The following formulation examples are illustrative only and are not intended to limit the scope of the present invention. Formulations In the formulations which follow, "active ingredient" means a compound of Formula I, or a salt or solvate thereof. Formulation 1: Gelatin Capsuleε Hard gelatin capεules are prepared using the following: Ingredient Quantity (mg/capsule) Active ingredient 0.1 - 1000 Starch, NF 0 - 650 Starch flowable powder 0 - 650 Silicone fluid 350 centistokes 0 - 15 The formulation above may be changed in compliance with the reasonable variationε provided. A tablet formulation is prepared using the ingredients below: Formulation 2 : Tablets Ingredient Quantity (mg/tablet) Active ingredient 2.5 - 1000 Cellulose, microcrystalline 200 - 650 Silicon dioxide, fumed 10 - 650 Stearate acid 5 - 15 The components are blended and compressed to form tablets. Alternatively, tablets each containing 2.5 - 1000 mg of active ingredient are made up as follows: Formulation 3 : Tablets Ingredient Quantity (mg/tablet) Active ingredient 25 - 1000 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrro1idone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium stearate 0.5 Talc 1 The active ingredient, starch, and cellulose are paεεed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then pasεed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°-60° C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets. Suspenεions each containing 0.1 - 1000 mg of medicament per 5 ml dose are made as followε: Formulation 4: Suεpensions Ingredient Quantity (mg/5 ml) Active ingredient 0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL Flavor q.v. Color q.v. Purified water to 5 mL The medicament iε passed through a No. 45 mesh U.S. sieve and mixed with the εodium carboxymethyl celluloεe and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume. An aerosol solution is prepared containing the following ingredients: Formulation 5: Aerosol Ingredient Quantity (% by weight) Active ingredient 0.25 Ethanol 25.75 Propellant 22 (Chlorodifluoromethane) 70.00 The active ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to 30° C, and transferred to a filling device. The reguired amount is then fed to a stainless steel container and diluted with the remaining propellant. The valve units are then fitted to the container. Suppositorieε are prepared as follows: Formulation 6: Suppositories Ingredient Quantity (mg/suppository) Active ingredient 250 Saturated fatty acid glycerides 2,000 The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previouεly melted using the minimal necessary heat. The mixture iε then poured into a εuppoεitory mold of nominal 2 g capacity and allowed to cool. An intravenous formulation is prepared aε followε: Formulation 7: Intravenous Solution Ingredient Quantity Active ingredient 50 mg Isotonic saline 1,000 mL The solution of the above ingredients is intravenouεly adminiεtered to a patient at a rate of about 1 mL per minute. Formulation 8: Combination Capsule I Ingredient Quantity (mg/capsule) Active ingredient 50 Premarin 1 Avicel pH 101 50 Starch 1500 117.50 Silicon Oil 2 Tween 80 0.50 Cab-O-Sil 0.25 Formulation 9 : Combination Capsule II Ingredient Quantity (mg/capsule) Active ingredient 50 Norethylnodrel 5 Avicel pH 101 82.50 Starch 1500 90 Silicon Oil 2 Tween 80 0.50 Formulation 10: Combination Tablet Ingredient Quantity (mg/capsule) Active ingredient 50 Premarin 1 Corn Starch NF 50 Povidone, K29-32 6 Avicel pH 101 41.50 Avicel pH 102 136.50 Crospovidone XL10 2.50 Magnesium Stearate 0.50 Cab-O-Sil 0.50

Claims: We claim: 1. A compound of Formula I: wherein each of R and R 1 is independently hydrogen, hydroxy, C 1 -C 4 ~alkoxy, benzyloxy, Ci-Cβ-alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituents each of which is independently halo, C 1 -C 4 - loweralkyl, or Cι-C 4 -loweralkoxy, Cχ- 5 -alkoxycarbonyloxy, or C 4 ~C 6 -alkylsulfonyloxy; R 3 is -CH=CH- (trans) or -CH 2 -CH 2 -; R 4 is hydroxy, Cι-C 4 ~alkoxy, or -N(R 5 ) 2 wherein each R 5 is taken separately and independently represents hydrogen or Ci-Cg-alkyl, or both R 5 are taken with the nitrogen atom to which they are attached to form pyrrolidino, piperidino, hexamethyleneimino, or morpholino; or a pharmaceutically acceptable salt thereof. A compound of Claim 1 wherein R 3 is -CH=CH- (trans) 3. A compound of Claim 2 wherein both of R and R 1 are methoxy. 4. A compound of Claim 2 wherein both of R and R 1 are hydroxy. 5. A compound of Claim 4 which is (E) -6-hydroxy- 3-[4- (2-carboxyvinyl)benzoyl] -2- (4- hydroxyphenyl)benzo[b]thiophene or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising a compound according to Claim 1, in combination with a pharmaceutically acceptable carrier, diluent or excipient. 7. A composition according to Claim 6 with the further limitation that R 3 is -CH=CH- (trans) . 8. A composition according to Claim 7 with the further limitation that both of R and R 1 are methoxy. 9. A composition according to Claim 7 with the further limitation that both of R and R 1 are hydroxy. 10. A composition according to Claim 9 wherein the compound is ( E) -6-hydroxy-3- [4- (2-carboxyvinyl)benzoyl] -2- (4- hydroxyphenyl)benzo[b] thiophene or a pharmaceutically acceptable salt thereof. 11. A method for alleviating a symptom of post¬ menopausal syndrome comprising administering to a woman in need of such treatment an effective amount of a compound of Claim 1. 12. A method according to Claim 11 wherein the symptom of menopausal syndrome is selected from osteoporosis or a cardiovascular disease. 13. A method according to Claim 12 wherein the cardiovascular disease is hyperlipidemia. 14. A method according to Claim 11 with the further limitation that R 3 is -CH=CH- (trans) . 15. A method according to Claim 14 with the further limitation that both of R and R 1 are methoxy. 16. A method according to Claim 14 with the further limitation that both of R and R 1 are hydroxy. 17. A method according to Claim 16 wherein the compound is (E) -6-hydroxy-3- [4- (2-carboxyvinyl)benzoyl]-2- (4- hydroxyphenyl)benzo[b]thiophene or a pharmaceutically acceptable salt thereof. 18. A compound of the formula wherein each of R a and R la is independently hydrogen, C 1 -C 4 - alkoxy, benzyloxy, Ci-Cg-alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituents each of which is independently halo, Cι-C 4 -loweralkyl, or Cχ-C 4 -loweralkoxy, Cχ_ 5 alkoxycarbonyloxy, or C 4 -C 6 ~alkylsulfonyloxy. 19. A compound of Claim 18 wherein both of R a and R la represent methoxy. 20. A method for the preparation of a compound of Formula lb: wherein each of R a and R l is independently hydrogen, C 2. -C 4 - alkoxy, benzyloxy, C 2 -Cg-alkanoyloxy, benzoyloxy, substituted benzoyloxy bearing 1 to 3 substituents each of which is independently halo, Cι-C 4 ~loweralkyl, or Cι-C 4 -loweralkoxy, Cι- 5 -alkoxycarbonyloxy, or C 4 -C 6 -alkylsulfonyloxy; R 3a is -CH=CH- (trans); and R 4 is Cι-C 4 -alkoxy, which comprises reacting a compound of Formula Ia with a trialkyl phosphonoacetate carbanion in an inert solvent at a temperature from -78°C to 0°. 21. The process of Claim 20 wherein both of R a and R la are methoxy. 22. The process of Claim 21 followed by hydrolysis and hydroxyl deprotection to the compound ( E) -6-hydroxy-3- (4- (2-carboxyvinyl)benzoyl) -2- (4- hydroxyphenyl)benzo (b) thiophene. 23. The process of Claim 22 followed by the further step of hydrogenation to the compound 6-hydroxy-3- (4- (2-carboxyethyl)benzoyl) -2- (4- hydroxyphenyl)benzo(b)thiophene.

Inventors: JONES CHARLES D, PALKOWITZ ALAN D, THRASHER KENNETH J, JONES, CHARLES, D., PALKOWITZ, ALAN, D., THRASHER, KENNETH, J.
Applicants: JONES CHARLES D, LILLY CO ELI, PALKOWITZ ALAN D, THRASHER KENNETH J, ELI LILLY AND COMPANY, JONES, CHARLES, D., PALKOWITZ, ALAN, D., THRASHER, KENNETH, J.
Application year: 1996
Main classification: C07D333
IPC codes: A61K31, A61P3, A61P9, A61P19, A61P43, C07D333